Tema Oncology ETF (NASDAQ:CANC) Short Interest Down 69.4% in March

Tema Oncology ETF (NASDAQ:CANC) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 2,200 shares, a decline of 69.4% from the February 28th total of 7,200 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 19,200 shares, the days-to-cover ratio is currently 0.1 days.

Hedge Funds Weigh In On Tema Oncology ETF

An institutional investor recently raised its position in Tema Oncology ETF stock. Thrivent Financial for Lutherans lifted its position in shares of Tema Oncology ETF (NASDAQ:CANC) by 29.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 517,837 shares of the company’s stock after purchasing an additional 118,328 shares during the period. Thrivent Financial for Lutherans owned about 20.31% of Tema Oncology ETF worth $13,156,000 as of its most recent SEC filing.

Tema Oncology ETF Price Performance

Shares of NASDAQ CANC opened at $24.69 on Friday. Tema Oncology ETF has a 1-year low of $23.97 and a 1-year high of $30.11. The company has a market capitalization of $62.97 million, a price-to-earnings ratio of 23.50 and a beta of 1.11. The business has a 50-day moving average of $25.27 and a 200-day moving average of $26.46.

About Tema Oncology ETF

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.